Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398943 · ClinicalTrials.gov registry record · NA
Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)
A NA study, sponsored by Augusta University.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT01398943 is a NA study that has completed, run by Augusta University. The registered enrollment target is 60 participants.
The verdict
NCT01398943, a NA study, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
More patients with chronic obstructive pulmonary disease (COPD) die from cardiovascular disease than direct pulmonary complications. Inflammation and oxidative stress, characteristic in COPD, are likely contributors to the reduction in nitric oxide (NO) bioavailability and vascular endothelial dysfunction in COPD patients; however, this has yet to be determined. Thus, the overall objective of this proposal is to identify the role of NO bioavailability in contributing to vascular endothelial dysfunction in patients with COPD and to provide insight into the molecular mechanisms involved. Our central hypothesis is that inflammation and oxidative stress, both independently, contribute to the reduction in NO bioavailability and vascular endothelial dysfunction in patients with COPD.
Interventions
- DRUG Tetrahydrobiopterin (BH4)
- DIETARY_SUPPLEMENT Antioxidant Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01398943
The ClinicalTrials.gov registry entry for NCT01398943 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tetrahydrobiopterin (BH4) is the first listed.
NCT01398943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01398943 about?
NCT01398943 is a clinical study titled "Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)". More patients with chronic obstructive pulmonary disease (COPD) die from cardiovascular disease than direct pulmonary complications. Inflammation and oxidative stress, characteristic in COPD, are likely contributors to the reduction in nitric oxide (NO) bioavailability and vascular endothelial dysfu...
What is the current status of trial NCT01398943?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2010-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01398943?
The interventions under investigation include: Tetrahydrobiopterin (BH4) (DRUG), Antioxidant Cocktail (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01398943?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.